Options for optimizing treatment of gastroesophageal reflux disease with proton pump inhibitors

Abstract

Proton pump inhibitors (PPI) were successfully used for the treatment of acid-base disorders, in particular GERD, for the past 20 years. However, approximately 30% of patients with gastroesophageal reflux disease (GERD) do not adequately respond to standard PPI therapy due to the impact of many factors: patient-specific PPI metabolism in the liver, concomitant pathology of the digestive system, pharmacokinetic properties of traditional dosage forms of PPI. Persistence of GERD symptoms is particularly explained by the fact that the use of conventional single release PPI does not allow to fully control the cyrcadian rhythm of gastric secretion and should be taken twice a day before a meal, which has a negative effect on adherence. Thanks to dual delayed-release and longer presence in blood, dexlansoprazole MR showed high efficacy in the treatment and maintaining remission of various forms of GERD, as well as greater adherence to treatment.

Keywords

• гастроэзофагеальная рефлюксная болезнь
• изжога
• ингибиторы протонной помпы
• декслансопразол
• mr
• gastroesophageal reflux disease
• heartburn
• proton pump inhibitors
• dexlansoprazole mr